Therapeutics discovery

Eli Lilly partnered with BigHat Biosciences to co-develop next-generation therapeutic antibodies using AI technology. BigHat's Milliner platform leverages machine learning and synthetic biology high-speed wet labs to optimize key antibody attributes for accelerated biologics development.

Eli LillyPharma

Latent Labs, led by ex-DeepMind scientist Dr. Simon Kohl, emerged as a generative AI service provider specializing in protein design for drug discovery. Using advanced AI, they aim to computationally design therapeutic molecules like antibodies and enzymes, revolutionizing treatments. Partnerships with Microsoft and renowned industry experts further strengthen their mission.

Latent LabsPharma

Pangaea Data partnered with Microsoft Azure to address inefficiencies in clinical trials and ensure data privacy. By leveraging Azure services, including Virtual Machines, Container Instances, Blob Storage, Health Data Services, and AI tools like Text Analytics for Health and OpenAI, they implemented a solution to characterize patients efficiently while preserving data privacy. This enabled clinicians and pharmaceutical companies to identify undiagnosed and misdiagnosed patients across 7,000 conditions. Key achievements included a collaboration between two pharmaceutical companies and the UK’s NHS, leading to improved trial efficiency, cost reductions, and significant financial savings. Through this partnership, Pangaea Data also expanded globally using the Azure Marketplace and Microsoft’s co-sell program.

Pangaea DataHealthcare